FDA peptide compounding 2026: what the Category 2 removals and the July PCAC review actually mean

Key takeaways

• On April 15, 2026, HHS Secretary Robert F. Kennedy Jr. announced that 12 peptides would be removed from the FDA's 503A interim Category 2 list, the bucket FDA uses for substances it considers to pose significant safety risks when used in compounding.
• The next day, April 16, 2026, FDA published a Federal Register notice scheduling a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23-24, 2026, to consider seven of those peptides for the 503A Bulks List: BPC-157, TB-500, KPV, MOTs-C, Emideltide (DSIP), Semax, and Epitalon.
• A further five peptides are scheduled for a separate PCAC meeting before the end of February 2027.
• Removal from Category 2 is not the same as being added to Category 1, and none of these peptides have ever been on Category 1. The PCAC's recommendation in July will be non-binding, and formal FDA rulemaking is still required before any of these substances are legally compoundable under section 503A.
• Patients and clinicians should treat the current regulatory status as uncertain, not as authorization. None of the peptides under review is FDA-approved for any human indication.

What actually happened in 2026

The story is easier to follow as a short timeline. In September 2023, FDA added a group of 19 peptides to the 503A interim Category 2 list, citing limited safety data and unresolved gaps in the published literature . Category 2 is the status FDA assigns to substances that have been nominated for compounding use but that the agency considers a significant safety risk, which in practice means the agency intends to take enforcement action against pharmacies that compound with them.

Kennedy began signaling his intent to reverse that posture in early 2026, and the wellness press tracked the promised move for weeks. The administrative action came on April 15, 2026, when Kennedy announced that the FDA would remove 12 specific peptides from Category 2 and that seven of them would be brought before the next PCAC meeting.

On April 16, 2026, FDA published a Federal Register notice formally establishing the PCAC meeting for July 23-24, 2026, with a public docket for comments . Regulatory-law analysts who reviewed the notice quickly stressed that this is the start of a process, not the end of one: removal from Category 2 does not by itself authorize compounding, and PCAC's vote will be a non-binding recommendation rather than a final regulatory action.

The seven peptides on the July PCAC agenda

The Federal Register notice and FDA's own meeting calendar list the same seven substances, in both free base and acetate salt forms, going to the July 23-24 PCAC meeting :

• BPC-157, a 15-amino-acid peptide marketed for tendon, gut, and soft-tissue healing. The pepSmart BPC-157 evidence map article covers the rodent literature and the human-trial gap in detail.
• TB-500, the synthetic fragment of Thymosin Beta-4 most commonly discussed for tendon and soft-tissue healing. Worth distinguishing from Thymosin Alpha-1, which is a different molecule and is not on the July agenda.
• KPV, a tripeptide fragment of alpha-MSH, marketed for inflammatory bowel and skin indications.
• MOTs-C, a mitochondrial-derived peptide explored for metabolic-health endpoints.
• Emideltide, also known as Delta Sleep-Inducing Peptide (DSIP), discussed for sleep architecture.
• Semax, a heptapeptide developed in Russia for cognitive and neurological endpoints. Selank, sometimes paired with Semax in community discussion, is not on the July agenda.
• Epitalon, also spelled Epithalon, a short peptide investigated for telomere and longevity endpoints.

Category 1, Category 2, and the 503A Bulks List, plainly

Section 503A of the Federal Food, Drug, and Cosmetic Act lets state-licensed compounding pharmacies prepare drug products for individual patients using bulk drug substances that fall into one of three lanes. The substance is the active ingredient powder before it is mixed into the patient-specific preparation.

• The lane most people mean by "approved for compounding" is the 503A Bulks List, a final list of substances that have cleared FDA review and may be used in 503A compounding without further question. Inclusion requires formal rulemaking after a PCAC recommendation.
• Category 1, the interim enforcement-discretion list, contains substances FDA is still evaluating but for which it has received enough information to set aside enforcement while the evaluation proceeds. Compounders generally treat Category 1 substances as usable on an interim basis at their own risk posture.
• Category 2 is the agency's significant-safety-risk bucket. FDA has said publicly that it intends to take regulatory action, including warning letters or seizures, against pharmacies that compound with Category 2 substances .

The peptides removed from Category 2 in April 2026 do not automatically land in Category 1. Regulatory analysts who reviewed the FDA action have stressed that these peptides were never on Category 1 in the first place, and Category 1 is the list of substances that may legally be used in section 503A compounding under interim enforcement discretion. The intended destination for the peptides currently under review is the 503A Bulks List, but that destination requires PCAC review followed by FDA rulemaking, neither of which has happened yet.

What the July PCAC meeting will and will not decide

PCAC is an advisory committee. Its job is to evaluate evidence on each nominated substance and recommend, by vote, whether FDA should add it to the 503A Bulks List. PCAC's recommendation is non-binding. FDA can adopt it, modify it, or set it aside. After the meeting, FDA still has to publish a proposed rule, accept public comment on that rule, and then publish a final rule before any peptide is actually on the Bulks List.

The Federal Register notice opened a public docket for comments. Comments submitted by July 9, 2026, will be provided to the committee; comments submitted by July 22, 2026, will still be considered by FDA . The meeting itself is scheduled to be held at FDA's White Oak campus, with a streaming option for the public.

The honest summary of the current state is continued regulatory uncertainty rather than a clear new pathway for compounding. The agency has lifted one specific enforcement posture (Category 2 listing) without yet replacing it with an affirmative authorization (Bulks List inclusion).

What this means for compounding pharmacies today

Removal from Category 2 is meaningful, because it lifts the explicit FDA position that these substances pose significant safety risks for compounding. It does not, by itself, create a legal pathway to compound with them under 503A. There is no Category 1 listing, no Bulks List inclusion, and no published rule authorizing compounding. Pharmacies that resume compounding with these peptides are operating in the same kind of regulatory uncertainty that existed before the 2023 Category 2 listing, not in a newly authorized environment.

The practical implications are that state boards of pharmacy, insurers, and FDA itself retain the discretion to act if they believe a particular compounding practice is unsafe or unlawful. Compounders considering whether to resume these preparations are weighing a political signal (the Kennedy announcement), a procedural signal (the Federal Register notice), and the underlying federal statute, which has not changed.

What this means for patients and clinicians today

None of the seven peptides under PCAC review is FDA-approved for any human indication. There is no DailyMed label, no prescribing information, and no agency-blessed dose for any of them. Even if PCAC recommends inclusion on the 503A Bulks List in July, and even if FDA later finalizes a rule adding them, that decision authorizes use of the substances in 503A compounding. It does not approve them as drugs. The unanswered questions about identity, purity, pharmacokinetics, and long-term safety that drove the 2023 Category 2 listing in the first place do not resolve themselves when the listing is reversed.

The pepSmart BPC-157 evidence map article is one example of how thin the human evidence base really is for this class. Rodent injury-healing data are broadly consistent for BPC-157, but no published phase 2 or phase 3 human efficacy trial exists. The same is true of every other peptide on the July agenda. None of them has a controlled human trial program that supports the kinds of efficacy claims that circulate in community discussion. The pepSmart SARMs regulatory-reality piece covers a parallel point for a different drug class: research-only labels and gray-market access do not turn an unapproved compound into an approved one.

The five-peptide second batch

Kennedy's April 15 announcement covered 12 peptides total. Seven go to the July 23-24 PCAC meeting. The remaining five are scheduled for a separate PCAC meeting that FDA has said will occur before the end of February 2027. Public reporting on that batch has identified candidates including Dihexa, Ibutamoren, Melanotan II, and Cathelicidin LL-37, although the formal Federal Register notice for that second meeting has not been published as of the date of this article.

The procedural path for the second batch is the same as for the first: PCAC vote, then FDA rulemaking. Nothing about being in the second batch implies a different outcome from the July agenda. Patients and pharmacies should treat the second batch the same way they treat the first: removed from Category 2, not yet authorized for compounding under 503A.

Open questions and what to watch

• What evidence package will FDA present to PCAC? The agency's briefing documents typically post a few days before each meeting. Those documents will be the clearest signal on how FDA reads the safety and efficacy literature today versus how it read it in 2023.
• How will PCAC vote on each substance? Each peptide is voted on individually. A split outcome (some recommended, some not) is plausible given the heterogeneity of the underlying literature.
• If PCAC recommends a substance, how fast will FDA move? The agency has historically taken months to a year or more between PCAC recommendations and final rulemaking. There is no statutory deadline.
• Will FDA continue to permit compounding under interim enforcement discretion while rulemaking is pending? The agency has not made a public commitment either way, and the regulatory-law briefings flagged this as an open question.
• Will any peptide currently outside the 12-peptide bucket (for instance, Thymosin Alpha-1, GHK-Cu, CJC-1295, or AOD-9604) be added to a future PCAC review? FDA has not announced additional peptides beyond the 12, but the political pressure to reconsider others appears to be ongoing.

Editorial summary

The 2026 changes are real and worth tracking, but the headline framing in some community write-ups is ahead of where FDA actually is. Twelve peptides have been removed from Category 2. Seven of them will be discussed at the PCAC meeting on July 23-24, 2026. None of them is on the 503A Bulks List. None of them is approved as a drug. Patients and clinicians who want to understand the current state of any specific peptide should consult the pepSmart compound library entries and the linked primary sources, and treat the regulatory posture as uncertain, not approved.